Prostate cancer patients weigh in: which chemo is easier to tolerate?
NCT ID NCT02044354
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether men with metastatic prostate cancer prefer cabazitaxel or docetaxel as their first chemotherapy. 195 patients tried both drugs in sequence and then stated their preference. The goal is to see if side effects like nerve damage or fatigue influence choice, helping doctors tailor treatment to what matters most to patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabazitaxel and docetaxel
What this could lead to
If this trial succeeds, it could help doctors choose which chemotherapy patients prefer based on side effects, improving quality of life during treatment.
What could go wrong
This is a completed Phase 3 study, but it only measures patient preference, not survival or cure. Results may not change standard care if one drug is clearly more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France